17-31232747-A-G
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 2P and 2B. PM2BP4BP6
The NM_001042492.3(NF1):c.3362A>G(p.Glu1121Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,613,886 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E1121K) has been classified as Uncertain significance.
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Publications
- neurofibromatosis type 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Genomics England PanelApp
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia
- Moyamoya diseaseInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001042492.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NF1 | NM_001042492.3 | MANE Select | c.3362A>G | p.Glu1121Gly | missense | Exon 26 of 58 | NP_001035957.1 | ||
| NF1 | NM_000267.4 | c.3362A>G | p.Glu1121Gly | missense | Exon 26 of 57 | NP_000258.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NF1 | ENST00000358273.9 | TSL:1 MANE Select | c.3362A>G | p.Glu1121Gly | missense | Exon 26 of 58 | ENSP00000351015.4 | ||
| NF1 | ENST00000356175.7 | TSL:1 | c.3362A>G | p.Glu1121Gly | missense | Exon 26 of 57 | ENSP00000348498.3 | ||
| NF1 | ENST00000579081.6 | TSL:1 | n.3362A>G | non_coding_transcript_exon | Exon 26 of 58 | ENSP00000462408.2 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152022Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.0000438 AC: 11AN: 251386 AF XY: 0.0000589 show subpopulations
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461864Hom.: 0 Cov.: 32 AF XY: 0.00000413 AC XY: 3AN XY: 727242 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152022Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74244 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Uncertain:1Benign:1
Hereditary cancer-predisposing syndrome Uncertain:1
Thep.E1121Gvariant (also known as c.3362A>G), located in coding exon 26 of theNF1gene, results from an A to G substitution at nucleotide position 3362. The glutamic acid at codon 1121 is replaced by glycine, an amino acid with similar properties. This alteration was reported in a father/son pair. Both of these individuals were described as having multiple café-au-lait spots, however, no other NF1-related clinical features were noted. The authors state that this exonic alteration produced mosaicism of E1121G and exon 20 (coding exon 26) skipping at the mRNA level due to a decreased ratio of ESE/ESSs. The mosaicism of the post-transcriptional profile was further examined using real-time PCR with cDNA obtained from this family; this assay demonstrated the skipping rate of the mutant exon in both individuals. The authors conclude that this is a disease causing mutation (Xu W,Int. J. Mol. Med.2014 Jul; 34(1):53-60.).This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.003% (greater than 30000 alleles tested) in our clinical cohort. Based on protein sequence alignment, this amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of p.E1121G remains unclear.
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Benign:1
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at